Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2612-2622

  Shen, Song ^a   Mao, Chong Qiong ^a   Yang, Xian Zhu ^a   Du, Xiao Jiao ^a   Liu, Yang ^a   Zhu, Yan Hua ^a   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

cationic lipid assisted polymeric nanoparticle; GATA2; non small cell lung carcinoma; siRNA delivery; synthetic lethal therapy

Indexed keywords

CATIONIC LIPID ASSISTED POLYMERIC NANOPARTICLE; K RAS PROTEIN; MESSENGER RNA; NANOPARTICLE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG; CATION; GATA2 PROTEIN, HUMAN; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; NANOMEDICINE; NUDE MOUSE; ONCOGENE RAS; PROCEDURES; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CATIONS; CELL LINE, TUMOR; CELL PROLIFERATION; GATA2 TRANSCRIPTION FACTOR; GENE SILENCING; GENES, RAS; HEPATOCYTES; HUMANS; LUNG NEOPLASMS; MICE, NUDE; MICROSCOPY, CONFOCAL; MUTATION; NANOMEDICINE; NANOPARTICLES; POLYMERS; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905453179     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400714z     Document Type: Article

References (55)

1. DeVita, V. T., Jr.; Chu, E. A history of cancer chemotherapy Cancer Res. 2008, 68, 8643-8653
2. Shawver, L. K.; Slamon, D.; Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy Cancer Cell 2002, 1 (2) 117-123
3. Druker, B. J. Perspectives on the development of a molecularly targeted agent Cancer Cell 2002, 1 (1) 31-36
4. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1 (7) 493-502
5. Subramanian, A.; Mokbel, K. The role of Herceptin in early breast cancer Int. Semin. Surg. Oncol. 2008, 5, 9
6. Force, T.; Kolaja, K. L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat. Rev. Drug Discovery 2011, 10 (2) 111-26
7. Janne, P. A.; Gray, N.; Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat. Rev. Drug Discovery 2009, 8 (9) 709-23
8. Kaelin, W. G., Jr. The concept of synthetic lethality in the context of anticancer therapy Nat. Rev. Cancer 2005, 5, 689-98
9. Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J. Clin. Oncol. 2008, 26 (22) 3785-3790
10. Dorr, J. R.; Yu, Y.; Milanovic, M.; Beuster, G.; Zasada, C.; Dabritz, J. H.; Lisec, J.; Lenze, D.; Gerhardt, A.; Schleicher, K.; Kratzat, S.; Purfurst, B.; Walenta, S.; Mueller-Klieser, W.; Graler, M.; Hummel, M.; Keller, U.; Buck, A. K.; Dorken, B.; Willmitzer, L.; Reimann, M.; Kempa, S.; Lee, S.; Schmitt, C. A. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy Nature 2013, 501, 421-425
11. Astsaturov, I.; Ratushny, V.; Sukhanova, A.; Einarson, M. B.; Bagnyukova, T.; Zhou, Y.; Devarajan, K.; Silverman, J. S.; Tikhmyanova, N.; Skobeleva, N.; Pecherskaya, A.; Nasto, R. E.; Sharma, C.; Jablonski, S. A.; Serebriiskii, I. G.; Weiner, L. M.; Golemis, E. A. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies Sci Signaling 2010, 3 (140) ra67
12. Yang, Y.; Shaffer, A. L., 3rd; Emre, N. C.; Ceribelli, M.; Zhang, M.; Wright, G.; Xiao, W.; Powell, J.; Platig, J.; Kohlhammer, H.; Young, R. M.; Zhao, H.; Xu, W.; Buggy, J. J.; Balasubramanian, S.; Mathews, L. A.; Shinn, P.; Guha, R.; Ferrer, M.; Thomas, C.; Waldmann, T. A.; Staudt, L. M. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma Cancer Cell 2012, 21 (6) 723-737
13. McManus, K. J.; Barrett, I. J.; Nouhi, Y.; Hieter, P. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 3276-3281
14. Molenaar, J. J.; Ebus, M. E.; Geerts, D.; Koster, J.; Lamers, F.; Valentijn, L. J.; Westerhout, E. M.; Versteeg, R.; Caron, H. N. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 12968-12973
15. Hatley, M. E.; Patrick, D. M.; Garcia, M. R.; Richardson, J. A.; Bassel-Duby, R.; van Rooij, E.; Olson, E. N. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21 Cancer Cell 2010, 18 (3) 282-293
16. Barbie, D. A.; Tamayo, P.; Boehm, J. S.; Kim, S. Y.; Moody, S. E.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Meylan, E.; Scholl, C.; Frohling, S.; Chan, E. M.; Sos, M. L.; Michel, K.; Mermel, C.; Silver, S. J.; Weir, B. A.; Reiling, J. H.; Sheng, Q.; Gupta, P. B.; Wadlow, R. C.; Le, H.; Hoersch, S.; Wittner, B. S.; Ramaswamy, S.; Livingston, D. M.; Sabatini, D. M.; Meyerson, M.; Thomas, R. K.; Lander, E. S.; Mesirov, J. P.; Root, D. E.; Gilliland, D. G.; Jacks, T.; Hahn, W. C. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 2009, 462, 108-112
17. Dolma, S.; Lessnick, S. L.; Hahn, W. C.; Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells Cancer Cell 2003, 3 (3) 285-296
18. Chia, N. Y.; Chan, Y. S.; Feng, B.; Lu, X.; Orlov, Y. L.; Moreau, D.; Kumar, P.; Yang, L.; Jiang, J.; Lau, M. S.; Huss, M.; Soh, B. S.; Kraus, P.; Li, P.; Lufkin, T.; Lim, B.; Clarke, N. D.; Bard, F.; Ng, H. H. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity Nature 2010, 468, 316-320
19. Silva, J. M.; Marran, K.; Parker, J. S.; Silva, J.; Golding, M.; Schlabach, M. R.; Elledge, S. J.; Hannon, G. J.; Chang, K. Profiling essential genes in human mammary cells by multiplex RNAi screening Science 2008, 319 (5863) 617-620
20. Yang, W. S.; Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells Chem. Biol. 2008, 15 (3) 234-45
21. Luo, J.; Emanuele, M. J.; Li, D.; Creighton, C. J.; Schlabach, M. R.; Westbrook, T. F.; Wong, K. K.; Elledge, S. J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 2009, 137, 835-848
22. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013 CA-Cancer J. Clin. 2013, 63 (1) 11-30
23. Yang, P.; Allen, M. S.; Aubry, M. C.; Wampfler, J. A.; Marks, R. S.; Edell, E. S.; Thibodeau, S.; Adjei, A. A.; Jett, J.; Deschamps, C. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 Chest 2005, 128 (1) 452-462
24. Heist, R. S.; Engelman, J. A. SnapShot: non-small cell lung cancer Cancer Cell 2012, 21 (3) 448 e2
25. Massarelli, E.; Varella-Garcia, M.; Tang, X.; Xavier, A. C.; Ozburn, N. C.; Liu, D. D.; Bekele, B. N.; Herbst, R. S.; Wistuba, II KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin. Cancer Res. 2007, 13 (10) 2890-6
26. Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med. 2005, 2 (1) e17
27. Chang, A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC Lung Cancer 2011, 71 (1) 3-10
28. Riely, G. J.; Marks, J.; Pao, W. KRAS mutations in non-small cell lung cancer Proc. Am. Thorac. Soc. 2009, 6 (2) 201-205
29. Winton, T.; Livingston, R.; Johnson, D.; Rigas, J.; Johnston, M.; Butts, C.; Cormier, Y.; Goss, G.; Inculet, R.; Vallieres, E.; Fry, W.; Bethune, D.; Ayoub, J.; Ding, K.; Seymour, L.; Graham, B.; Tsao, M. S.; Gandara, D.; Kesler, K.; Demmy, T.; Shepherd, F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N. Engl. J. Med. 2005, 352 (25) 2589-2597
30. Lopez-Chavez, A.; Carter, C. A.; Giaccone, G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer Curr. Opin. Invest. Drugs 2009, 10, 1305-1314
31. Garassino, M. C.; Marabese, M.; Rusconi, P.; Rulli, E.; Martelli, O.; Farina, G.; Scanni, A.; Broggini, M. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer Ann. Oncol. 2011, 22 (1) 235-237
32. Karnoub, A. E.; Weinberg, R. A. Ras oncogenes: split personalities Nat. Rev. Mol. Cell Biol. 2008, 9 (7) 517-531
33. Hutchinson, L. Targeted therapies: Progress for KRAS mutant NSCLC Nat. Rev. Clin. Oncol. 2013, 10 (2) 66
34. Chan, D. A.; Giaccia, A. J. Harnessing synthetic lethal interactions in anticancer drug discovery Nat. Rev. Drug Discovery 2011, 10 (5) 351-364
35. Kumar, M. S.; Hancock, D. C.; Molina-Arcas, M.; Steckel, M.; East, P.; Diefenbacher, M.; Armenteros-Monterroso, E.; Lassailly, F.; Matthews, N.; Nye, E.; Stamp, G.; Behrens, A.; Downward, J. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer Cell 2012, 149, 642-655
36. Barbacid, M. Opening a new GATAway for treating KRAS-driven lung tumors Cancer Cell 2012, 21 (5) 598-600
37. Steckel, M.; Molina-Arcas, M.; Weigelt, B.; Marani, M.; Warne, P. H.; Kuznetsov, H.; Kelly, G.; Saunders, B.; Howell, M.; Downward, J.; Hancock, D. C. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies Cell Res. 2012, 22 (8) 1227-1245
38. Iorns, E.; Lord, C. J.; Turner, N.; Ashworth, A. Utilizing RNA interference to enhance cancer drug discovery Nat. Rev. Drug Discovery 2007, 6 (7) 556-68
39. Kim, D. H.; Rossi, J. J. Strategies for silencing human disease using RNA interference Nat. Rev. Genet. 2007, 8 (3) 173-84
40. Pai, S. I.; Lin, Y. Y.; Macaes, B.; Meneshian, A.; Hung, C. F.; Wu, T. C. Prospects of RNA interference therapy for cancer Gene Ther. 2006, 13, 464-77
41. Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. RNA interference in the clinic: challenges and future directions Nat. Rev. Cancer 2011, 11, 59-67
42. Stevenson, M. Therapeutic potential of RNA interference N. Engl. J. Med. 2004, 351 (17) 1772-1777
43. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides Mol. Pharmaceutics 2009, 6, 686-695
44. Howard, K. A. Delivery of RNA interference therapeutics using polycation-based nanoparticles Adv. Drug Delivery Rev. 2009, 61, 710-720
45. Liu, X. Q.; Xiong, M. H.; Shu, X. T.; Tang, R. Z.; Wang, J. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth Mol. Pharmaceutics 2012, 9, 2863-2874
46. Yu, H.; Zou, Y.; Jiang, L.; Yin, Q.; He, X.; Chen, L.; Zhang, Z.; Gu, W.; Li, Y. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles Biomaterials 2013, 34, 2738-2747
47. Dou, S.; Yao, Y. D.; Yang, X. Z.; Sun, T. M.; Mao, C. Q.; Song, E. W.; Wang, J. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy J. Controlled Release 2012, 161, 875-883
48. Yao, Y. D.; Sun, T. M.; Huang, S. Y.; Dou, S.; Lin, L.; Chen, J. N.; Ruan, J. B.; Mao, C. Q.; Yu, F. Y.; Zeng, M. S.; Zang, J. Y.; Liu, Q.; Su, F. X.; Zhang, P.; Lieberman, J.; Wang, J.; Song, E. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis Sci. Transl. Med. 2012, 4 (130) 130ra48
49. Lee, J. M.; Yoon, T. J.; Cho, Y. S. Recent developments in nanoparticle-based siRNA delivery for cancer therapy Biomed Res. Int. 2013, 2013, 782041
50. Yang, X. Z.; Dou, S.; Sun, T. M.; Mao, C. Q.; Wang, H. X.; Wang, J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy J. Controlled Release 2011, 156, 203-211
51. Kaelin, W. G., Jr. Synthetic lethality: a framework for the development of wiser cancer therapeutics Genome Med. 2009, 1 (10) 99
52. Wang, Z.; Rao, D. D.; Senzer, N.; Nemunaitis, J. RNA interference and cancer therapy Pharm. Res. 2011, 28, 2983-2995
53. Wang, X. L.; Xu, R.; Wu, X.; Gillespie, D.; Jensen, R.; Lu, Z. R. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice Mol. Pharmaceutics 2009, 6, 738-46
54. Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution Mol. Pharmaceutics 2008, 5, 487-495
55. Lee, H.; Hoang, B.; Fonge, H.; Reilly, R. M.; Allen, C. In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels Pharm. Res. 2010, 27, 2343-2355